# JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03557970** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Edicotinib
- **OTHER:** Pharmacokinetic Study

## Key facts

- **NCT ID:** NCT03557970
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-05
- **Primary completion:** 2020-09-28
- **Final completion:** 2020-09-28
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Not enough enrollment to determine efficacy
- **Last updated:** 2021-12-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557970, "JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03557970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*